Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Executive Officer | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 461,425 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,905 · Balance 461,425 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,183 | $21.15 | $151,920.45 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 11 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,517 | $108.00 | $595,836.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 10 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,517 | $7.15 | $39,446.55 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 9 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,500 | $108.00 | $810,000.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 8 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,500 | $11.46 | $85,950.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 7 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,826 | $108.00 | $845,208.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 6 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,826 | $14.37 | $112,459.62 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 5 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,010 | $117.00 | $118,170.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 526 | $115.03 | $60,508.30 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,168 F3 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 526 shares in multiple trades at prices ranging from $115.00 to $115.59. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 417 | $108.00 | $45,036.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,694 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,345 | $119.01 | $279,073.06 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,111 F1 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 2,345 shares in multiple trades at prices ranging from $119.00 to $119.07. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 11,609 | $73.20 Strike: $73.20 | $849,778.80 |
DisclosureSEC source: 0001645113-22-000093 · wf-form4_166750812638914.xml · derivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,609 Underlying: Ordinary Shares · 11,609 shares Expires 2032-10-31 F2 · shares: Options to buy 11,609 ordinary shares will vest and become exercisable in equal installments on each of November 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000093 · wf-form4_166750812638914.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,456 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of November 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:35 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $76.01 | $513,371.54 |
DisclosureSEC source: 0001645113-22-000086 · wf-form4_166603866486448.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,626 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $84.37 | $569,834.98 |
DisclosureSEC source: 0001645113-22-000085 · wf-form4_166517377413417.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,380 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $77.35 | $522,421.90 |
DisclosureSEC source: 0001645113-22-000084 · wf-form4_166456919628442.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,134 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $77.00 | $520,058.00 |
DisclosureSEC source: 0001645113-22-000083 · wf-form4_166422355748808.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,888 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,517 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · derivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,517 Underlying: Ordinary Shares · 5,517 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,517 | $90.00 | $496,530.00 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,642 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $87.31 | $589,691.74 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,159 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,517 | $7.15 | $39,446.55 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,863 | $88.00 | $163,944.00 |
DisclosureSEC source: 0001645113-22-000080 · wf-form4_166301475766544.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,150 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 08, 2022 Filed Sep 13, 2022 20:15 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,754 | $81.48 | $550,315.92 |
DisclosureSEC source: 0001645113-22-000081 · wf-form4a_166310011170112.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,396 F1 · security: Amending original Form 4 filed on September 12, 2022 to add additional transaction inadvertently omitted. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 20:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,384 | $78.57 | $108,740.88 |
DisclosureSEC source: 0001645113-22-000079 · wf-form4_166258244880634.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,013 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 584 | $79.04 | $46,157.61 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 13 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,397 F14 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 48 | $78.96 | $3,789.89 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 12 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,981 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F13 · price: On September 1, 2022, Mr. Leonard sold 48 shares in multiple trades at prices ranging from $78.70 to $79.28. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 438 | $78.14 | $34,225.32 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 11 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,029 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F12 · price: On September 1, 2022, Mr. Leonard sold 438 shares in multiple trades at prices ranging from $77.59 to $78.58. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 360 | $77.06 | $27,742.32 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 10 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,467 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F11 · price: On September 1, 2022, Mr. Leonard sold 360 shares in multiple trades at prices ranging from $76.57 to $77.48. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 240 | $75.88 | $18,210.00 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 9 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,827 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F10 · price: On September 1, 2022, Mr. Leonard sold 240 shares in multiple trades at prices ranging from $75.42 to $76.41. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,088 | $78.68 | $85,601.66 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 8 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,067 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F9 · price: On September 1, 2022, Mr. Leonard sold 1,088 shares in multiple trades at prices ranging from $78.46 to $79.28. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,720 | $77.92 | $211,934.24 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 7 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,155 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F8 · price: On September 1, 2022, Mr. Leonard sold 2,720 shares in multiple trades at prices ranging from $77.42 to $78.39. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,750 | $76.96 | $134,676.50 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 6 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,875 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F7 · price: On September 1, 2022, Mr. Leonard sold 1,750 shares in multiple trades at prices ranging from $76.41 to $77.33. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,200 | $75.93 | $91,113.60 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 5 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,625 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F6 · price: On September 1, 2022, Mr. Leonard sold 1,200 shares in multiple trades at prices ranging from $75.41 to $76.31. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 452 | $78.66 | $35,555.68 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,825 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · price: On September 1, 2022, Mr. Leonard sold 452 shares in multiple trades at prices ranging from $78.57 to $78.74. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,955 | $78.09 | $230,741.18 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,277 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F4 · price: On September 1, 2022, Mr. Leonard sold 2,955 shares in multiple trades at prices ranging from $77.57 to $78.56. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,914 | $77.00 | $147,381.83 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,232 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F3 · price: On September 1, 2022, Mr. Leonard sold 1,914 shares in multiple trades at prices ranging from $76.54 to $77.42. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,047 | $75.94 | $79,503.95 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,146 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F2 · price: On September 1, 2022, Mr. Leonard sold 1,047 shares in multiple trades at prices ranging from $75.42 to $76.37. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 414 | $69.66 | $28,838.83 |
DisclosureSEC source: 0001645113-22-000069 · wf-form4_165955941387882.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,193 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:46 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 312 | $59.08 | $18,431.40 |
DisclosureSEC source: 0001645113-22-000060 · wf-form4_165723038363274.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,607 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 744 | $70.10 | $52,154.40 |
DisclosureSEC source: 0001645113-22-000029 · wf-form4_164686288571914.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,295 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 555 | $70.41 | $39,075.89 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,039 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 4,933 | $80.59 Strike: $80.59 | $397,550.47 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · derivative · entry 5 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,933 Underlying: Ordinary Shares · 4,933 shares Expires 2032-02-29 F4 · shares: Options to buy 4,933 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 30,422 | $80.59 Strike: $80.59 | $2,451,708.98 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · derivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,422 Underlying: Ordinary Shares · 30,422 shares Expires 2032-02-29 F3 · shares: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 930 | $74.50 | $69,283.14 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,594 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 17,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,524 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 540 | $138.23 | $74,645.28 |
DisclosureSEC source: 0001645113-21-000109 · wf-form4_163104715467852.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,153 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 328 | $149.43 | $49,013.04 |
DisclosureSEC source: 0001645113-21-000098 · wf-form4_162811199885199.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,158 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 713 | $149.38 | $106,506.51 |
DisclosureSEC source: 0001645113-21-000098 · wf-form4_162811199885199.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,486 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:36 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 154 | $137.12 | $21,116.79 |
DisclosureSEC source: 0001645113-21-000088 · wf-form4_162578019833894.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,199 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:07 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 765 | $130.81 | $100,066.59 |
DisclosureSEC source: 0001645113-21-000044 · wf-form4_161541045494629.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,045 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.